Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Reshma Mahtani; Lisa Hineman

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Reshma Mahtani
, Lisa Hineman

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of the Advanced Practitioner in Oncology
Volume	10
State	Published - 2019

Disciplines

Medicine and Health Sciences

Cite this

@article{445e5ce3ec6f4ae3a6edfe6dd5bed3e3,

title = "Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management",

author = "Reshma Mahtani and Lisa Hineman",

note = "Although breast cancer is a heterogeneous disease, approximately 20\% to 25\% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic breast cancer in 1998 represented a major breakthrough for p ...",

year = "2019",

language = "American English",

volume = "10",

journal = "Journal of the Advanced Practitioner in Oncology",

}

TY - JOUR

T1 - Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

AU - Mahtani, Reshma

AU - Hineman, Lisa

N1 - Although breast cancer is a heterogeneous disease, approximately 20% to 25% of patients diagnosed with breast cancer have amplification of the HER2 gene. The FDA approval of trastuzumab for the treatment of HER2-positive (HER2+) metastatic breast cancer in 1998 represented a major breakthrough for p ...

PY - 2019

Y1 - 2019

UR - https://pubmed.ncbi.nlm.nih.gov/31538025/

M3 - Article

VL - 10

JO - Journal of the Advanced Practitioner in Oncology

JF - Journal of the Advanced Practitioner in Oncology

ER -

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Disciplines

Other files and links

Cite this